And for pancreatic cancer treatment

Israel’s Tiltan Pharma Ltd has begun a Phase II clinical trial of its TL-118 drug for the treatment of pancreatic cancer. The trial will include 80 patients at three Israeli hospitals. TL-118 prevents blood flow to tumours, preventing their growth. Scientists at the Hebrew University of Jerusalem developed the drug.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published.